LNSR Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -269.38%. LENSAR, Inc.'s return on equity of -1013.45% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.

LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 42.99%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 1632.1%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than LENSAR, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than LENSAR, Inc..

LENSAR, Inc. has a beta of 0.665, which suggesting that the stock is 33.53% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.

LENSAR, Inc. quarterly revenues are $14.3M, which are larger than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. LENSAR, Inc.'s net income of -$3.7M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.10x versus 1.38x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -162.05%. LENSAR, Inc.'s return on equity of -1013.45% beat Standard BioTools, Inc.'s return on equity of -24.44%.

LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 42.99%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.65 which suggests that it could grow by 7.64%. Given that LENSAR, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe LENSAR, Inc. is more attractive than Standard BioTools, Inc..

LENSAR, Inc. has a beta of 0.665, which suggesting that the stock is 33.53% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.585%.

LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.

LENSAR, Inc. quarterly revenues are $14.3M, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. LENSAR, Inc.'s net income of -$3.7M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.10x versus 4.24x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Movano, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -5036.25%. LENSAR, Inc.'s return on equity of -1013.45% beat Movano, Inc.'s return on equity of -410.28%.

LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 42.99%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 2976.92%. Given that Movano, Inc. has higher upside potential than LENSAR, Inc., analysts believe Movano, Inc. is more attractive than LENSAR, Inc..

LENSAR, Inc. has a beta of 0.665, which suggesting that the stock is 33.53% less volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.

LENSAR, Inc. quarterly revenues are $14.3M, which are larger than Movano, Inc. quarterly revenues of $80K. LENSAR, Inc.'s net income of -$3.7M is higher than Movano, Inc.'s net income of -$4M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.10x versus 14.76x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NeuroPace, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -12.78%. LENSAR, Inc.'s return on equity of -1013.45% beat NeuroPace, Inc.'s return on equity of -149.8%.

LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 42.99%. On the other hand NeuroPace, Inc. has an analysts' consensus of $17.13 which suggests that it could grow by 5.04%. Given that LENSAR, Inc. has higher upside potential than NeuroPace, Inc., analysts believe LENSAR, Inc. is more attractive than NeuroPace, Inc..

LENSAR, Inc. has a beta of 0.665, which suggesting that the stock is 33.53% less volatile than S&P 500. In comparison NeuroPace, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. NeuroPace, Inc. pays out -- of its earnings as a dividend.

LENSAR, Inc. quarterly revenues are $14.3M, which are smaller than NeuroPace, Inc. quarterly revenues of $27.4M. LENSAR, Inc.'s net income of -$3.7M is lower than NeuroPace, Inc.'s net income of -$3.5M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while NeuroPace, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.10x versus 5.59x for NeuroPace, Inc.. Usually stocks with elevated PS ratios are considered overvalued.